Yield10 Bioscience

Yield10 Bioscience LT Debt/Equity

Long-Term Debt to Equity Ratio of Yield10 Bioscience (YTENQ) as of Nov 4, 2026.

LT Debt/Equity

0.00

Last updated:

Long-Term Debt to Equity Ratio of Yield10 Bioscience is 2019 0.00 . Long-Term Debt to Equity Ratio of Yield10 Bioscience was 2018 0.00 . It decreases by % lower compared to the previous year.

The Yield10 Bioscience LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2014
0.00 USD
Jan 1, 2015
0.00 USD
Jan 1, 2016
0.00 USD
Jan 1, 2017
0.00 USD
Jan 1, 2018
0.00 USD
Jan 1, 2019
0.00 USD
The Yield10 Bioscience LT Debt/Equity history
YEARLT Debt/EquityYoY
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Yield10 Bioscience Stock analysis

What does Yield10 Bioscience do? Yield10 Bioscience develops Camelina sativa as a platform crop for low carbon sustainable seed products, including Camelina oil for biofuel feedstock, Omega-3 oils for nutrition, and PHA Bioplastics for biodegradable packaging. The company uses its TraitFactory platform to discover genetic traits for agriculture and food industries, focusing on herbicide tolerance and disease resistance in Camelina germplasm. Its products target petroleum replacement markets, food and nutrition sectors, and animal feed markets, with development pipelines focused on improving Camelina varieties. The company's primary products are Camelina oil, Omega-3 oils, and PHA Bioplastics, sold to markets addressing petroleum replacement, nutrition, and sustainable packaging needs. Camelina sativa serves as the core crop for all seed product development, with TraitFactory enabling trait discovery for agricultural and food applications. The firm targets industrial buyers in biofuel, nutrition, and packaging industries seeking sustainable alternatives to petroleum-based products. Yield10 Bioscience's revenue streams come from the sale of Camelina-based products to companies in the biofuel, nutrition, and packaging sectors. The company focuses on developing high-value genetic traits through TraitFactory, which are integrated into Camelina varieties for large-scale production of seed products. Its development pipeline emphasizes traits like herbicide tolerance and disease resistance to enhance crop performance and market appeal. Yield10 Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Yield10 Bioscience stock

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Yield10 Bioscience since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Yield10 Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Yield10 Bioscience

All Key Metrics — Yield10 Bioscience